Credit Suisse Group started coverage on shares of AveXis (NASDAQ:AVXS) in a report published on Wednesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $134.00 target price on the stock.

A number of other equities analysts have also commented on AVXS. Wells Fargo & Co restated an outperform rating on shares of AveXis in a research report on Friday, September 29th. BMO Capital Markets restated an outperform rating and issued a $123.00 price target on shares of AveXis in a research report on Saturday, September 30th. Citigroup boosted their price target on shares of AveXis from $100.00 to $116.00 and gave the company a buy rating in a research report on Monday, October 2nd. UBS Group restated a buy rating and issued a $122.00 price target (up from $95.00) on shares of AveXis in a research report on Tuesday, October 3rd. Finally, Goldman Sachs Group reiterated a buy rating and set a $130.00 target price on shares of AveXis in a research report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the company. AveXis currently has a consensus rating of Buy and an average price target of $113.89.

AveXis (AVXS) traded down $1.92 during trading hours on Wednesday, reaching $108.25. 777,156 shares of the company’s stock were exchanged, compared to its average volume of 547,921. The firm has a market capitalization of $3,885.53, a price-to-earnings ratio of -19.40 and a beta of 2.46. AveXis has a 52-week low of $50.56 and a 52-week high of $119.00.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the business posted ($0.87) EPS. equities research analysts anticipate that AveXis will post -6.23 earnings per share for the current year.

In other news, VP Andrew F. Knudten sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $94.48, for a total transaction of $188,960.00. Following the transaction, the vice president now directly owns 7,000 shares in the company, valued at $661,360. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the transaction, the vice president now owns 1,780 shares in the company, valued at $180,242.80. The disclosure for this sale can be found here. Insiders have sold 57,340 shares of company stock worth $5,851,445 over the last quarter. 18.60% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Strs Ohio bought a new stake in shares of AveXis during the third quarter worth approximately $116,000. Ameritas Investment Partners Inc. raised its stake in shares of AveXis by 331.0% during the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after buying an additional 1,622 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of AveXis by 688.6% during the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of AveXis during the third quarter worth approximately $200,000. Finally, Deschutes Portfolio Strategy LLC bought a new stake in shares of AveXis during the third quarter worth approximately $203,000. 92.88% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/01/21/avexis-avxs-receives-new-coverage-from-analysts-at-credit-suisse-group.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.